Physician profile
Robert K King
NPI 1861470940
$3,651.76
in general payments reported to CMS, 2019-2025
27 companies · $35.12 in 2025
The $35.12 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $403 · 2021: $776 · 2022: $609 · 2023: $845 · 2024: $214 · 2025: $35.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,034.78 | 2019-2024 | Myrbetriq |
| Janssen Biotech, INC. | $551.81 | 2019-2024 | Erleada |
| Boston Scientific Corporation | $422.88 | 2019-2024 | Moses 550 D\F\L, Greenlight Xps, Rezum Generator |
| Abbvie INC. | $211.56 | 2019-2022 | |
| Convatec INC. | $178.27 | 2022-2023 | |
| Procept Biorobotics Corporation | $175.31 | 2023 | Aquabeam Robotic System |
| Neotract INC. | $113.71 | 2020 | |
| Coloplast Corp | $110.94 | 2020-2025 | Saffron, Titan |
| Tolmar Pharmaceuticals, INC. | $104.65 | 2019-2022 | |
| Pfizer INC. | $100.46 | 2019-2021 | |
| Myovant Sciences INC. | $89.89 | 2021 | |
| Ferring Pharmaceuticals INC. | $83.01 | 2019-2024 | Adstiladrin |
| 180 Medical, INC. | $71.11 | 2023-2024 | Gentlecath Glide, Gentlecath |
| Teleflex LLC | $66.70 | 2021-2023 | Urolift |
| Merck Sharp & Dohme LLC | $40.19 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $37.94 | 2022 | |
| Cook Medical LLC | $35.58 | 2020-2023 | Resonance |
| Genzyme Corporation | $34.51 | 2019 | |
| Innovation Technologies INC | $33.86 | 2023 | Irrisept |
| Ambu INC. | $23.44 | 2020 | |
| Medtronic, INC. | $22.41 | 2022 | |
| Isoray, INC | $22.28 | 2020 | |
| Progenics Pharmaceuticals, INC. | $20.22 | 2024 | |
| Olympus America INC. | $18.47 | 2023 | Olympus |
| Tolmar, INC. | $17.66 | 2024 | |
| Laborie Medical Technologies Corp. | $16.84 | 2023 | |
| Dendreon Pharmaceuticals LLC | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.